Argenica Therapeutics Limited (AGN.AX)
AUD 0.76
(4.83%)
AUD 0.76
(4.83%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -1.89 Million AUD | 0.0% |
| 2023 | - AUD | -61.98% |
| 2022 | - AUD | -297.3% |
| 2021 | - AUD | -168.32% |
| 2020 | - AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | - AUD | 100.0% |
| 2024 Q4 | -4.45 Million AUD | 0.0% |
| 2024 FY | - AUD | -24.82% |
| 2024 Q2 | -3.81 Million AUD | -10979.77% |
| 2024 Q1 | 25.73 Thousand AUD | 101.6% |
| 2023 Q2 | -2.94 Million AUD | -29129.62% |
| 2023 FY | - AUD | -61.98% |
| 2023 Q4 | -3.67 Million AUD | -18648.86% |
| 2023 Q3 | 19.81 Thousand AUD | 100.67% |
| 2023 Q1 | 10.16 Thousand AUD | 100.43% |
| 2022 FY | - AUD | -297.3% |
| 2022 Q3 | 213.00 AUD | 100.01% |
| 2022 Q2 | -2 Million AUD | -319488.54% |
| 2022 Q1 | 628.00 AUD | 100.06% |
| 2022 Q4 | -2.34 Million AUD | -1101400.47% |
| 2021 FY | - AUD | -168.32% |
| 2021 Q2 | -230.84 Thousand AUD | -744745.16% |
| 2021 Q4 | -1.09 Million AUD | -1824866.67% |
| 2021 Q1 | 31.00 AUD | 100.01% |
| 2021 Q3 | 60.00 AUD | 100.03% |
| 2020 Q2 | -200.00 AUD | 0.0% |
| 2020 FY | - AUD | 0.0% |
| 2020 Q4 | -383.45 Thousand AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | 64.215% |
| Acrux Limited | -7.93 Million AUD | 76.074% |
| Actinogen Medical Limited | -12.92 Million AUD | 85.314% |
| AnteoTech Limited | -11.57 Million AUD | 83.6% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 78.517% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -30.27% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 90.304% |
| Amplia Therapeutics Limited | -4.55 Million AUD | 58.382% |
| Avecho Biotechnology Limited | -3.24 Million AUD | 41.478% |
| Bio-Gene Technology Limited | -2.97 Million AUD | 36.215% |
| Biome Australia Limited | -1.57 Million AUD | -20.234% |
| Biotron Limited | -5.04 Million AUD | 62.35% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 86.367% |
| BTC Health Limited | 1.05 Million AUD | 279.818% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 83.207% |
| CSL Limited | 4.73 Billion AUD | 100.04% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 95.75% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 103.659% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 80.929% |
| Dimerix Limited | -24.95 Million AUD | 92.397% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 118.289% |
| Hexima Limited | -995.54 Thousand AUD | -90.609% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | 32.665% |
| Immuron Limited | -6.19 Million AUD | 69.356% |
| Immutep Limited | -42.87 Million AUD | 95.574% |
| Imugene Limited | -147.97 Million AUD | 98.718% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -163.393% |
| Memphasys Limited | -3.3 Million AUD | 42.631% |
| Nanollose Limited | -1.14 Million AUD | -65.31% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 100.952% |
| Noxopharm Limited | -5.94 Million AUD | 68.084% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -5.64% |
| Nyrada Inc. | -4.59 Million AUD | 58.714% |
| Orthocell Limited | -11.68 Million AUD | 83.755% |
| PharmAust Limited | -9.45 Million AUD | 79.923% |
| Patrys Limited | -3.49 Million AUD | 45.661% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 97.06% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 75.941% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 73.592% |
| PYC Therapeutics Limited | -38.11 Million AUD | 95.022% |
| Race Oncology Limited | -14.2 Million AUD | 86.64% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 95.818% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 91.114% |
| Starpharma Holdings Limited | -12.57 Million AUD | 84.912% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 108.263% |
| Tissue Repair Ltd | -5.77 Million AUD | 67.141% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 94.793% |